

Pharmaceutical Policies Updates Effective February 1, 2020

MVP Health Care® (MVP) provides a listing of all current medical and pharmaceutical policies. To view these policies, *Sign In* at mvphealthcare.com/providers and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication is sent out one month prior to the effective date, listing the policies and their status. These policies can fall into one of the following categories:

- **New** – Denotes a new policy.
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs.
- **Review/No Changes**– Policies that have been reviewed but have no content change.
- **Archived** – Denotes a policy that is not active.

The following policies are effective February 1, 2020 (unless otherwise noted) and will be available for viewing on or before January 1, 2020.

Pharmaceutical Policy Name	Status
Minocycline ER	No changes
Doryx/Oracea	No changes
Hepatitis C Treatment	No changes
Mepron (atovaquone)	Updated
Crohn’s Disease, Select Agents: Effective 1/1/20	Updated
Infertility Drug Therapy (Commercial/Marketplace): Effective 1/1/20	Updated
Antibiotic/Antiviral (oral) Prophylaxis	No changes
Lyme Disease/IV Antibiotic Treatment	Updated
Zinplava	No changes
Government Programs Over the Counter (OTC) Drug Coverage	No changes
Compounded (Extemporaneous) Medications	No changes
Transthyretin-Mediated Amyloidosis Therapy	Updated
Xolair: Effective 12/2/19	Updated
Spinal Muscular Atrophy (SMA): Effective 12/2/19	Updated
Luxturna	No changes